Ratings InventisBio Co., Limited

Equities

688382

CNE100005Q22

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
8.63 ^CNY	-0.46%		-4.54%	-43.00%

04-29	InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-11	Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
INVENTISBIO CO., LIMITED	-43.00%	687M	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B	B+
BIONTECH SE	-10.84%	22.71B	B+
ARGENX SE	-1.46%	21.83B	B
GENMAB A/S	-11.02%	18.18B	A-
WUXI APPTEC CO., LTD.	-41.92%	16.52B	A-
BEIGENE, LTD.	-15.11%	16.01B	B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B	C+
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes